Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC

A Phase I, Open-Label, Randomized, Four Period Crossover Drug Interaction Study to Evaluate the Pharmacokinetic Profiles of VYVANSE™ and ADDERALL XR When Each is Administered Alone and in Combination With the Proton Pump Inhibitor Prilosec OTC™ in Healthy Adult Volunteers

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00746733

Enrollment

Registered

2008-09-04

Start date

2008-09-08

Completion date

2008-10-26

Last updated

2021-06-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteers

Keywords

Drug, Interaction, Study

Brief summary

The purpose of this study is to determine if taking Vyvanse with Prilosec OTC or Adderall XR with Prilosec OTC changes how quickly the drug is absorbed into the body and/or changes how much of the drug is absorbed into the body.

Interventions

DRUGLisdexamfetamine Dimesylate

50mg capsule

DRUGAdderall XR (mixed salts amphetamine)

20mg capsule

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

1. Healthy volunteers, age 18 to 45 inclusive at the time of consent. 2. Male, or non-pregnant, non-lactating female 3. Female subjects must have a negative serum beta Human Chorionic Gonadotropin (HCG) pregnancy test at Screening, and a negative urine pregnancy test on Day -1 after checking into the clinic the day before the first dose of investigational product. 4. Body Mass Index (BMI) between 20.0 and 30.0 kg/m² inclusive. This inclusion criterion will only be assessed at the first screening visit. 5. Satisfactory medical assessment with no significant or relevant abnormality in medical history, physical examination (PE), vital signs and laboratory evaluation 6. Normal or clinically insignificant Screening ECG findings as assessed by the Investigator. 7. Ability to swallow investigational products.

Exclusion criteria

1. Current or recurrent disease that could affect the action, absorption or disposition of the investigational products, or could affect clinical or laboratory assessments. 2. Current or relevant previous history of physical or psychiatric illness, any medical disorder that may require treatment or make the subject unlikely to fully comply with the requirements of the study or complete the study, or any condition that presents undue risk from the investigational products or study procedures. 3. Significant illness, as judged by the Investigator, within 2 weeks of the first dose of investigational product. 4. History of significant anxiety, tension or agitation as assessed by the Investigator. 5. History of or current diagnosis of glaucoma. 6. History of a seizure disorder (other than infantile febrile seizures), any tic disorder or a current diagnosis and/or known family history of Tourette's Disorder. 7. History of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, transient ischemic attack or stroke or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant drug. 8. History of controlled or uncontrolled hypertension or a resting sitting systolic blood pressure \>139mmHg or diastolic blood pressure \>89mmHg. 9. Known family history of sudden cardiac death or ventricular arrhythmia. 10. Currently considered a suicide risk, has previously made a suicide attempt or has a prior history of, or is currently demonstrating suicidal ideation. 11. Current use of any medication (including prescription, over the counter \[OTC\], herbal or homeopathic preparations) with the exception of hormonal replacement therapy or hormonal contraceptives (Current use is defined as use within 14 days of first dose of investigational product). 12. Use of any medication known to inhibit or induce the CYP450 enzymes responsible for the metabolism of the investigational products within 14 days of first dose of investigational product. 13. Known or suspected intolerance or hypersensitivity to the investigational product(s), closely related compounds or any of the stated ingredients. 14. History of alcohol or other substance abuse within the last year.

Design outcomes

Primary

Measure	Time frame	Description
T 1/2 of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC	0 through 96 hours after dosing	Total amphetamine is the d- and l-amphetamines.
Cmax of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC	0 through 96 hours after dosing	l-Amphetamine is an isomer of Adderall XR and is an active form that is responsible for the drug's therapeutic activity.
Tmax of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC	0 through 96 hours after dosing	l-Amphetamine is an isomer of Adderall XR and is an active form that is responsible for the drug's therapeutic activity.
AUC of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC	0 through 96 hours after dosing	—
T 1/2 of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC	0 through 96 hours after dosing	l-Amphetamine is an isomer of Adderall XR and is an active form that is responsible for the drug's therapeutic activity.
Cmax of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC	0 through 96 hours after dosing	Total amphetamine is the d- and l-amphetamines.
Tmax of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC	0 through 96 hours after dosing	Total amphetamine is the d- and l-amphetamines.
AUC of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC	0 through 96 hours after dosing	Total amphetamine is the d- and l-amphetamines.
Maximum Plasma Concentration (Cmax) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC	0 through 96 hours after dosing	d-Amphetamine is an isomer of Vyvanse and Adderall XR and is an active form that is responsible for the drug's therapeutic activity.
Time of Maximum Plasma Concentration (Tmax) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC	0 through 96 hours after dosing	d-Amphetamine is an isomer of Vyvanse and Adderall XR and is an active form that is responsible for the drug's therapeutic activity.
Area Under the Steady-state Plasma Concentration-time Curve (AUC) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC	0 through 96 hours after dosing	d-Amphetamine is an isomer of Vyvanse and Adderall XR and is an active form that is responsible for the drug's therapeutic activity.
Terminal Half-life (T 1/2) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC	0 through 96 hours after dosing	d-Amphetamine is an isomer of Vyvanse and Adderall XR and is an active form that is responsible for the drug's therapeutic activity.

Secondary

Measure	Time frame	Description
DRQ-S, Question 1, for Vyvanse and Adderall XR in Combination With Prilosec OTC	Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12 and 24 hours after dosing	Question 1: How much do you feel the drug now? Questions are rated on a 29-point scale from 1 (not at all) to 29 (an awful lot). The higher the score the stronger the subjective experience. This is a subjective measure of a drug's effect that has been used to assess the abuse potential of drugs.
DRQ-S, Question 3, for Vyvanse and Adderall XR in Combination With Prilosec OTC	Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12 and 24 hours after dosing	Question 3: Do you dislike the drug effect you are feeling now? Questions are rated on a 29-point scale from 1 (not at all) to 29 (an awful lot). The higher the score the stronger the subjective experience. This is a subjective measure of a drug's effect that has been used to assess the abuse potential of drugs.
Systolic Blood Pressure for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC	Pre-dose and 1, 2, 4, 8, 12, 24, 48, 72 and 96 hours after dosing	—
Diastolic Blood Pressure for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC	Pre-dose and 1, 2, 4, 8, 12, 24, 48, 72 and 96 hours after dosing	—
Pulse Rate for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC	Pre-dose and 1, 2, 4, 8, 12, 24, 48, 72 and 96 hours after dosing	—
Electrocardiogram Results (QTcF Interval) for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC	Pre-dose, 2 and 8 hours after dosing	QTcF is the QT interval using Fridericia's correction formula. QT interval is a measure of time between the start of the Q wave and the end of the T wave and is dependent on the heart rate(e.g., the faster the heart rate, the shorter the QT interval). The QT interval has to be corrected in order to aid interpretation.
Drug Rating Questionnaire-Subject (DRQ-S), Question 2, for Vyvanse and Adderall XR in Combination With Prilosec OTC.	Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12 and 24 hours after dosing	Question 2: How much do you like the effects you are feeling now? Questions are rated on a 29-point scale from 1 (not at all) to 29 (an awful lot). The higher the score the stronger the subjective experience. This is a subjective measure of a drug's effect that has been used to assess the abuse potential of drugs.

Countries

United States

Participant flow

Pre-assignment details

Open-label, randomized, four period crossover

Participants by arm

Arm	Count
Entire Study Population	24
Total	24

Withdrawals & dropouts

Period	Reason	FG000	FG001
Second Intervention	Adverse Event	1	0
Third Intervention	Withdrawal by Subject	1	1

Baseline characteristics

Characteristic	Entire Study Population
Age, Categorical <=18 years	0 Participants
Age, Categorical >=65 years	0 Participants
Age, Categorical Between 18 and 65 years	24 Participants
Age, Continuous	37.7 years STANDARD_DEVIATION 6.54
Region of Enrollment United States	24 Participants
Sex: Female, Male Female	6 Participants
Sex: Female, Male Male	18 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk
deaths Total, all-cause mortality	— / —	— / —	— / —	— / —
other Total, other adverse events	8 / 24	3 / 23	10 / 21	3 / 21
serious Total, serious adverse events	0 / 24	0 / 23	0 / 21	0 / 21

Outcome results

Primary

Area Under the Steady-state Plasma Concentration-time Curve (AUC) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC

d-Amphetamine is an isomer of Vyvanse and Adderall XR and is an active form that is responsible for the drug's therapeutic activity.